These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 17240536)

  • 1. Radiotherapy for prostate cancer.
    Elconin JH
    N Engl J Med; 2007 Jan; 356(3):309-10; author reply 310-1. PubMed ID: 17240536
    [No Abstract]   [Full Text] [Related]  

  • 2. Duration of testosterone suppression and the risk of death from prostate cancer in men treated with radiation and 6 months of hormone therapy.
    Palma D; Pickles T
    Cancer; 2008 May; 112(10):2322-3; author reply 2323. PubMed ID: 18327816
    [No Abstract]   [Full Text] [Related]  

  • 3. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
    Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and management of erectile dysfunction after various treatments for prostate cancer.
    Soh J; Kaiho Y; Kikuchi E; Oya M; Yoshioka K; Nakagami Y; Hatano T; Ozu C; Horiguchi Y; Namiki K; Tachibana M; Hisasue S; Tanaka N; Asakawa I
    Int J Urol; 2010 Aug; 17(8):689-97. PubMed ID: 20590940
    [No Abstract]   [Full Text] [Related]  

  • 5. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
    Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of prostate cancer].
    Imre R
    Orv Hetil; 2005 Aug; 146(35):1839-42. PubMed ID: 16187544
    [No Abstract]   [Full Text] [Related]  

  • 7. RE: Three-dimensional conformal radiotherapy in the treatment of prostate cancer in Australia and New Zealand: report on a survey of radiotherapy centres by K-H Tai et al.
    Izard MA
    Australas Radiol; 2005 Jun; 49(3):256-7. PubMed ID: 15932473
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of prostate cancer with hormonal therapy in Europe.
    Miller K; Anderson J; Abrahamsson PA
    BJU Int; 2009 Mar; 103 Suppl 2():2-6. PubMed ID: 19228146
    [No Abstract]   [Full Text] [Related]  

  • 9. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy.
    D'Amico AV; Renshaw AA; Loffredo B; Chen MH
    Cancer; 2007 Oct; 110(8):1723-8. PubMed ID: 17828774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer?
    Kollmeier MA; Zelefsky MJ
    Nat Clin Pract Urol; 2008 Nov; 5(11):584-5. PubMed ID: 18813218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global update on the use of hormonal therapy for the management of high-risk prostate cancer: introduction.
    Gomella LG
    BJU Int; 2007 Jan; 99 Suppl 1():1. PubMed ID: 17229158
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of the hormone sensitivity of prostate cancer: where are we now?
    Alcaraz A
    Eur Urol; 2008 Aug; 54(2):247-50; discussion 250-1. PubMed ID: 18343562
    [No Abstract]   [Full Text] [Related]  

  • 13. Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist.
    Boudreaux KJ; Chang SS
    BJU Int; 2008 Mar; 101(6):671-4. PubMed ID: 18070172
    [No Abstract]   [Full Text] [Related]  

  • 14. Adjuvant treatment to radiation: combined hormone therapy and external radiotherapy for locally advanced prostate cancer.
    Bolla M; Descotes JL; Artignan X; Fourneret P
    BJU Int; 2007 Jul; 100 Suppl 2():44-7. PubMed ID: 17594359
    [No Abstract]   [Full Text] [Related]  

  • 15. [LHRH agonists in prostate cancer].
    Rossi D; Cornu JN; Rouprêt M
    Prog Urol; 2007 Apr; 17(2 Suppl 1):287-90. PubMed ID: 17569272
    [No Abstract]   [Full Text] [Related]  

  • 16. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
    Bruchovsky N; Klotz L; Crook J; Goldenberg SL
    Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.
    Vikram B
    J Natl Cancer Inst; 2006 Dec; 98(24):1826; author reply 1826. PubMed ID: 17179485
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiple intracrine hormonal targets in the prostate: opportunities and challenges.
    Labrie F
    BJU Int; 2007 Jul; 100 Suppl 2():48-51. PubMed ID: 17594360
    [No Abstract]   [Full Text] [Related]  

  • 19. [Preliminary results of radical surgery and radiotherapy of locally advanced prostate cancer (basal PSA >50 ng/ml)].
    Kaprin AD; Khmelevskiĭ EV; Fadeev AV
    Vopr Onkol; 2007; 53(4):479-81. PubMed ID: 17969415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer.
    Yoon FH; Gardner SL; Danjoux C; Morton G; Cheung P; Choo R
    J Urol; 2008 Oct; 180(4):1438-43; discussion 1443-4. PubMed ID: 18710743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.